All In Biotech

Drug Trial Radar · NCT00417079

XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer

A Randomized, Open Label Multi-Center Study of XRP6258 at 25 mg/m^2 in Combination With Prednisone Every 3 Weeks Compared to Mitoxantrone in Combination With Prednisone For The Treatment of Hormone Refractory Metastatic Prostate Cancer Previously Treated With A Taxotere®-Containing Regimen

Last checked: Nov 19, 2026Latest source record: Mar 10, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 755 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

755

Actual

Start

Jan 2007

Primary completion

Sep 2009

Study completion Sep 2009

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Dec 29, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, open-label, multi-center study comparing the safety and efficacy of XRP6258 plus prednisone to mitoxantrone plus prednisone in the treatment of hormone refractory metastatic prostate cancer previously treated with a Taxotere®-containing regimen. The primary objective is overall survival. Secondary objectives include progression free survival, overall response rate, prostate-specific antigen (PSA) response/progression, pain response/progression, overall safety, and pharmacokinetics. Patients will be treated until disease progression, death, unacceptable toxicity, or for a maximum of 10 cycles. Patients will have long-term follow-up for a maximum of up to 2 years.

Conditions

  • Neoplasms
  • Prostatic Neoplasms

Interventions

  • cabazitaxel (XRP6258) (RPR116258)Drug

    25 mg/m\^2 administered by intravenous (IV) route over 1 hour on day 1 of each 21-day cycle

  • mitoxantroneDrug

    12 mg/m\^2 administered by intravenous (IV) route over 15-30 minutes on day 1 of each 21-day cycle

  • prednisoneDrug

    10 mg daily administered by oral route

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: From the date of randomization up to 104 weeks (study cut-off)

Locations

26 sites in 26 countries. Site status is shown where the registry gives one.

  • sanofi-aventis US

    Bridgewater, New Jersey

  • sanofi-aventis Argentina

    Buenos Aires, Argentina

  • sanofi-aventis Belgium

    Diegem, Belgium

  • sanofi-aventis Brazil

    São Paulo, Brazil

  • sanofi-aventis Canada

    Laval, Quebec, Canada

  • sanofi-aventis Chile

    Santiago, Chile

  • sanofi-aventis Czech Republic

    Prague, Czechia

  • sanofi-aventis Denmark

    Hørsholm, Denmark

  • sanofi-aventis Finland

    Helsinki, Finland

  • sanofi-aventis France

    Paris, France

  • sanofi-aventis Germany

    Berlin, Germany

  • Sanofi-Aventis Hungaria

    Budapest, Hungary

  • sanofi-aventis India

    Mumbai, India

  • sanofi-aventis Italy

    Milan, Italy

  • sanofi-aventis Mexico

    México, Mexico

  • sanofi-aventis Netherlands

    Gouda, Netherlands

  • sanofi-aventis Russia

    Moscow, Russia

  • sanofi-aventis Singapore

    Singapore, Singapore

  • sanofi-aventis Slovakia

    Bratislava, Slovakia

  • sanofi-aventis South Africa

    Midrand, South Africa

  • sanofi-aventis South Korea

    Seoul, South Korea

  • sanofi-aventis Spain

    Barcelona, Spain

  • sanofi-aventis Sweden

    Bromma, Sweden

  • sanofi-aventis Taiwan

    Taipei, Taiwan

  • sanofi-aventis Turkey

    Istanbul, Turkey (Türkiye)

  • sanofi-aventis UK

    Guildford, Surrey, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.